



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/31, C07K 14/295, A61K 31/70, 39/118	A2	(11) International Publication Number: WO 99/51745 (43) International Publication Date: 14 October 1999 (14.10.99)
(21) International Application Number: PCT/CA99/00292 (22) International Filing Date: 7 April 1999 (07.04.99) (30) Priority Data: 09/055,765 7 April 1998 (07.04.98) US (71) Applicant (for all designated States except US): UNIVERSITY OF MANITOBA [CA/CA]; Dept. of Medical Microbiology, Room 543, 730 William Avenue, Winnipeg, Manitoba R3E 0W3 (CA). (72) Inventor; and (75) Inventor/Applicant (for US only): BRUHNAM, Robert, C. [CA/CA]; University of Manitoba, Dept. of Medical Microbiology, Room 543, 730 William Avenue, Winnipeg, Manitoba R3E 0W3 (CA). (74) Agent: STEWART, Michael, I.; Sim & McBurney, 6th floor, 330 University Avenue, Toronto, Ontario M5G 1R7 (CA).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: DNA IMMUNIZATION AGAINST <i>CHLAMYDIA</i> INFECTION (57) Abstract Nucleic acid, including DNA, for immunization to generate a protective immune response in a host, including humans, to a major outer membrane protein of a strain of <i>Chlamydia</i> , preferably contains a nucleotide sequence encoding a fragment that generates antibodies that specifically react with MOMP and a promoter sequence operatively coupled to the first nucleotide sequence for expression of the MOMP fragment in the host. The non-replicating vector may be formulated with a pharmaceutically-acceptable carrier for <i>in vivo</i> administration to the host.		